Mr Rosen is an Executive Director of Phosphagenics Limited and is a non-practicing lawyer.  He is one of the founders of Betatene Ltd and Denehurst Ltd, two formerly ASX listed companies which commercialised significant research and development.  Betatene is the world's largest producer of natural beta carotene.  After the purchase of Betatene Ltd by Henkel Corporation, Mr Rosen served as Vice President, Corporate Development. As a Vice President of Henkel Corporation, he worked for a number of years in the US in the nutrition and health care industries.

Mr Rosen has consulted to many technology companies assisting them with the commercialisation of new technologies.  He has had significant experience in the areas of seed capital raising, stock exchange listings, taxation and corporate law.  Mr Rosen graduated from the Australian National University (BA - Psychology) in 1970 and Melbourne University (LLB) in 1973.

Dr Ogru was appointed Joint CEO of Phosphagenics in April 2010.  As an Executive Director she is responsible for the strategic direction of the organisation, as well as oversight of operations and financial activities.  She plays an active role in driving key development programs, commercial negotiations and general corporate activity.  She leads a team of experienced pharmaceutical scientists, chemists and strategic collaborators.

In this role, Dr Ogru has developed commercial opportunities for both the Company’s nutraceutical division and pharmaceutical technologies, such as transdermal drug delivery and drug enhancement platforms for cancer, heart disease and chronic pain management.  Further, Dr Ogru has many years experience in both the academic and commercial aspects of the industry and has numerous publications in peer-reviewed journals.

Fred Banti (B.S., M.S.)
President, Phosphagenics Inc.

Mr Banti joined Phosphagenics in 2008 as Senior Vice President and Chief Business Officer working out of its New York office.

He has more than 29 years experience as a pharmaceutical executive with strong management credentials in corporate, business and strategy development, portfolio and project management, commercial assessments and R&D.  He possesses a thorough understanding of the drug development and commercialisation process.

From 2006 to 2008, he was VP Business Development for Gemin X Inc.; a private Venture backed Oncology Company.  Prior to that, he was VP Life Sciences at Wood Mackenzie, VP Corporate Development for Penwest Pharmaceutical, VP Global Business Development for Novartis Oncology and Senior Director, Corporate Licensing and Global Head of Infectious Disease Licensing at Pharmacia (now Pfizer). These senior appointments followed 18 years in a variety of research and commercial positions within Rhone Poulenc Rorer (now Sanofi Aventis), culminating in his appointment from 1994-1999 as Director, Corporate Worldwide Business Development and Licensing.

Mr Banti graduated from Fairfield University (BS, Biology) in 1979 and the University of Pennsylvania (MS, Organizational Planning) in 1990. He is a non executive Director of Atlantic Healthcare Limited in the UK.

Paul Gavin (BSc (Hons), PhD)
Vice President, Reseach & Development

Dr Gavin is responsible for the global coordination and management of the company’s pre-clinical and clinical research.

Since joining the Company in 2002, Dr Gavin has developed opportunities in both the Company’s pharmaceutical and nutraceutical divisions such as transdermal drug delivery systems and drug enhancement platforms for chronic pain management.  He is an inventor of the TPM platform technology for transdermal delivery, and has managed its development from discovery to clinical development with a range of products.

Dr Gavin holds a Bachelor of Science (Hons) and a PhD in Biochemistry & Molecular Biology from Monash University, Melbourne.  He is experienced in many aspects of academic and commercial research and development and has published in peer journals.

Dr Libinaki joined the company in 2002 and since this time has been involved and managed a wide range of pre-clinical and clinical development programs.  Her focus has been on oral drug delivery systems and drug enhancement platforms to improved bioavailibity and/or efficacy of a range of nutraceticals and pharmaceuticals for the purpose of improving health and wellbeing.   Dr Libinaki is responsible for  the management of the Nutraceutical department.

Dr Libinaki holds a Bachelor of Science (Biomedical, Hons) and a PhD in Biochemistry & Molecular Biology from Monash University, Melbourne.  She has collaborated and overseen numerous academic and commercial research programs and has published in peer reviewed journals.

Divyang Butala (BSc (Hons), PhD)
Vice President, Bioanalytical and CMC

Dr Butala joined the Company in 2009 and is responsible for the management of the Bioanalytical and CMC Department.  He is also responsible for the smooth scale-up of products from the Chemistry laboratory to the Hallmarc manufacturing facility where the process is validated and locked-in.

He has more than 15 years experience in Pharmaceutical industry - including R&D/QC Laboratory management, process development and scale-up of new drug candidates for clinical trials in Australia and overseas.  During this period Dr Butala gained considerable expertise in preparing technical data packages for TMF, DMF and IND submission to TGA and FDA.